Polymorphisms of the interleukin 10 gene promoter in patients from Brazil with epidermodysplasia verruciformis

Journal of the American Academy of Dermatology

Volumn 49, Issue 4, 2003, Pages 639-643

  De Oliveira, Walmar Roncalli P ^b   Rady, Peter L ^b   Grady, James ^b   Hughes, Thomas K ^b   Neto, Cyro Festa ^b   Rivitti, Evandro A ^b   Tyring, Stephen K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ARTICLE; CANCER SUSCEPTIBILITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; DNA POLYMORPHISM; DOWN REGULATION; EPIDERMODYSPLASIA VERRUCIFORMIS; HUMAN; MALIGNANT TRANSFORMATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN BIOPSY; SKIN CANCER; VERRUCA VULGARIS; WART VIRUS;

EID: 0141644364     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0190-9622(03)01567-6     Document Type: Article

References (33)

1. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995;131:1312-8.
2. Majewski S, Jablonska S. Human papillomavirus-associated tumors of the skin and mucosa. J Am Acad Dermatol 1997;36:659-85.
3. Majewski S, Jablonska S. Immunology of HPV infection and HPV-associated tumors. Int J Dermatol 1998;37:81-95.
4. Majewski S, Jablonska S. Epidermodysplasia verruciformis. In: Sterling JC, Tyring SK, eds. Human papillomaviruses clinical and scientific advances. New York: Oxford University Press; 2001. p. 90-101.
5. Majeswki S, Jablonska S. Do epidermodysplasia verruciformis human papillomaviruses contribute to malignant and benign epidermal proliferations? Arch Dermatol 2002;138:629-54.
6. Cooper KD, Androphy EJ, Lowy D, Katz SI. Antigen presentation and T cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990;94:769-76.
7. Majewski S, Skopinska-Rosewska E, Jablonska S, Wasik M, Misiewick J, Orth G. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1986;15:966-73.
8. Jablonska S, Majewski S. Epidermodysplasia verruciformis: immunological and clinical aspects. Curr Top Microbiol Immunol 1994;186:157-75.
9. Glinski W, Obalek S, Jablonska S, et al. T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. Dermatologica 1981;161:141-7.
10. Schroder JM. Cytokine networks in the skin. J Invest Dermatol 1995;105(Suppl):20-4S.
11. Matsue H, Cruz PD, Bergstresser PR, Takashima A. Cytokine expression by epidermal cell subpopulations. J Invest Dermatol 1992;99:42-5.
12. Frazer IH. Immunology of papillomavirus infection. Curr Opin Immunol 1996;8:484-91.
13. Asadullah K, Sabat R, Wiese A, et al. Interleukin-10 in cutaneous disorder: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 1999;291:628-36.
14. Majewski S, Jablonska S, Orth G. Epidermodysplasia verruciformis: immunological and nonimmunological surveillance mechanisms; role in tumor progression. Clin Dermatol 1997;15:321-34.
15. Kim J, Modlin RL, Moy RL, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. J Immunol 1995;155:2240-7.
16. Turner DM, Williams DM, Sankaran D, Lozarus M, Sinnoss PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
17. Gibson AW, Edberg JC, Wu J, Westendorp RGJ, Huizinga TWJ, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of lupus erythematosus. J Immunol 2001;166:391-2.
18. Eskdale J, Gallagher G, Vermeij CL, Keijsers V, Westendorp RGJ. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998;95:9465-70.
19. Edward-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powel EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-30.
20. Lowe PR, Galley HF. A novel PCR-rFLP assay for detection of the single nucleotide polymorphism at position -1082 in the human IL-10 gene promoter. Eur J Immunogenet 2001;28:563-4.
21. Coakely G, Mokk CC, Hajeer AH, Ollier WE, Turner D, Sinnott PJ, et al. Interleukin-10 promoter polymorphism in rheumatoid and Felty's syndrome. Br J Rheumatol 1998;37:988-91.
22. Perrey C, Pravica V, Sinnot PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-γ interleukin-10, transforming growth factor-β1 and tumour necrosis factor-α genes: a technical report. Transplant Immunol 1998;6:193-7.
23. Lim S, Crawley E, Woo P, Barnes P. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 1998;352:113.
24. Haanpaa M, Nurmikko T, Hurme M. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis 2002;34:114.
25. Helminen M, Lahdenpohja N, Hurme M. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis 1996;180:496-9.
26. Howell WM, Turner SJ, Bateman AC,Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2:25-31.
27. Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer 2001;94:792-4.
28. Row JW, Kim MH, Seo SS, Kim SH, Kim JW, P NH, et al. Interleukin-10 promoter polymorphism and cervical cancer risk in Korean women. Cancer Lett 2002;182:57-63.
29. Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991;147:528-33.
30. Majewski S, Hunzelsmann N, Nischt R, Eckes B, Rudnicka L, Orth G, et al. The observed effect is due to another function of the IL-10, S TGFβ-1 and TNF-α expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991;97:862-7.
31. Streilein JW. Sunlight and skin-associated lymphoid tissue (SALT): if UVB is the trigger and TNF-α is the mediator, what is the message? J Invest Dermatol 1992;100:47-52.
32. Albo D, Granick MS, Jhala N, Atkinson B, Solomon MP. The relationship of angiogenesis to biological activity in squamous cell carcinoma of the head-and-neck. Ann Plast Surg 1994;32:841-4.
33. Kundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 1997;180:55-61.